26 May 2026

strategyland.uk

GSK plc (GSK)

Rank #43 of 100 - Healthcare - UK Equities

Home/Stocks/Healthcare

GSK plc

GSK.L·Healthcare·Market Cap £76.7b

Rank #43 of 100

Data from Excel Model · 100 Stocks Analysed

£19.01

+4.06% YTD

Target: £20.63(+8.5%)

52W: £13.15 - £22.82

Score Analysis

GSK plc is ranked #43 out of 100 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

42/100

Average Score

Liquidity

Weak64/100

Valuation

Excellent8/100

Profitability

Weak73/100

Solvency

Excellent14/100

Asset Efficiency

Weak89/100

Mkt Trading

Excellent9/100

Technical

Good37/100

1. Valuation

Score: 8/100

Is GSK undervalued compared to its peers and fair value metrics?

3/5

valuation criteria met

✓

FY26e P/E Ratio

10.4xRank 17/100

✓

FY27e P/E Ratio

9.6xRank 16/100

✗

Price-to-Book

4.54xRank 71/100

✗

Price-to-Tangible Book

N/ARank 101/100

✓

EV/EBITDA

7.2xRank 25/100

Key Valuation Metrics

Current P/E

13.3x

Price-to-Earnings

FY26e P/E

10.4x

Forward estimate

FY27e P/E

9.6x

Forward estimate

P/B Ratio

4.54x

Price-to-Book

P/TBV

N/A

Price-to-Tangible Book

EV/EBITDA

7.2x

Enterprise Value

FY26e EV/EBITDA

7.8x

Forward estimate

FY27e EV/EBITDA

7.8x

Forward estimate

Analyst Consensus Target

Current Price

£19.01

Consensus Target

£20.63

Potential

+8.5%

Target

Bloomberg Median Target: £19.80

2. Profitability

Score: 73/100

How profitable is GSK relative to its peers?

0/6

profitability criteria met

✗

TTM Profit Margin

19.4%Rank 67/100

–

Current ROE

38.0%

–

Current ROA

N/A

✗

FY26e EPS

1.96Rank 66/100

–

TTM EPS

1.88

–

Net Income Growth

N/A

Profit Margin

19.4%

ROE

38.0%

FY27e ROE

35.1%

ROA

N/A

Earnings Per Share

3. Financial Health

Score: 14/100

How strong is GSK's balance sheet and financial position?

0/4

solvency criteria met

–

Debt-to-Equity

111.1%

–

Interest Coverage

N/A

✗

Debt/EBITDA

Rank 71Rank 71/100

–

Altman Z-Score

2.29

Key Health Metrics

Quick Ratio

0.54

Below 1.0

Cash Ratio

0.82

Debt/Equity

111%

FCF Margin

1.0%

Altman Z-Score

2.29

Grey Zone

01.812.995+

4. Asset Efficiency

Score: 89/100

How efficiently does GSK deploy its assets and intellectual capital?

1/2

asset efficiency criteria met

–

Intangible/Asset

Intangible assets as a proportion of total assets — lower indicates more tangible, capital-efficient operations

N/A

✓

R&D/Sales

Research & development spend relative to revenue — balanced R&D investment signals sustainable growth

Rank 2/100

Overall Asset Efficiency Rank

Rank within sector peers#89/100

Best (1)Worst (100)

What This Measures

Intangible/Asset — a lower ratio suggests the company's value is backed by tangible assets rather than goodwill or intangibles, reducing balance sheet risk.

R&D/Sales — captures the proportion of revenue reinvested into research and development, indicating innovation intensity and future growth investment.